JP2011503008A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503008A5
JP2011503008A5 JP2010532334A JP2010532334A JP2011503008A5 JP 2011503008 A5 JP2011503008 A5 JP 2011503008A5 JP 2010532334 A JP2010532334 A JP 2010532334A JP 2010532334 A JP2010532334 A JP 2010532334A JP 2011503008 A5 JP2011503008 A5 JP 2011503008A5
Authority
JP
Japan
Prior art keywords
use according
antibody
treatment
symptoms
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010532334A
Other languages
English (en)
Japanese (ja)
Other versions
JP5767475B2 (ja
JP2011503008A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/082481 external-priority patent/WO2009061818A1/en
Publication of JP2011503008A publication Critical patent/JP2011503008A/ja
Publication of JP2011503008A5 publication Critical patent/JP2011503008A5/ja
Application granted granted Critical
Publication of JP5767475B2 publication Critical patent/JP5767475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010532334A 2007-11-05 2008-11-05 強皮症の治療方法 Active JP5767475B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99617507P 2007-11-05 2007-11-05
US60/996,175 2007-11-05
US10045408P 2008-09-26 2008-09-26
US61/100,454 2008-09-26
PCT/US2008/082481 WO2009061818A1 (en) 2007-11-05 2008-11-05 Methods of treating scleroderma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014075310A Division JP2014144966A (ja) 2007-11-05 2014-04-01 強皮症の治療方法

Publications (3)

Publication Number Publication Date
JP2011503008A JP2011503008A (ja) 2011-01-27
JP2011503008A5 true JP2011503008A5 (enExample) 2011-12-08
JP5767475B2 JP5767475B2 (ja) 2015-08-19

Family

ID=43087976

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010532334A Active JP5767475B2 (ja) 2007-11-05 2008-11-05 強皮症の治療方法
JP2014075310A Pending JP2014144966A (ja) 2007-11-05 2014-04-01 強皮症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014075310A Pending JP2014144966A (ja) 2007-11-05 2014-04-01 強皮症の治療方法

Country Status (21)

Country Link
US (1) US20110008365A1 (enExample)
EP (1) EP2219452B1 (enExample)
JP (2) JP5767475B2 (enExample)
KR (1) KR20100098620A (enExample)
CN (1) CN101909444B (enExample)
AU (1) AU2008324800B2 (enExample)
BR (1) BRPI0819195A2 (enExample)
CA (1) CA2703705A1 (enExample)
CY (1) CY1117251T1 (enExample)
DK (1) DK2219452T3 (enExample)
ES (1) ES2557352T3 (enExample)
HR (1) HRP20151403T1 (enExample)
HU (1) HUE025787T2 (enExample)
IL (1) IL205452A (enExample)
MX (1) MX2010004814A (enExample)
NZ (1) NZ585064A (enExample)
PL (1) PL2219452T3 (enExample)
PT (1) PT2219452E (enExample)
RU (1) RU2530561C2 (enExample)
SI (1) SI2219452T1 (enExample)
WO (1) WO2009061818A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
RU2013157177A (ru) * 2011-05-25 2015-06-27 МЕДИММЬЮН, ЭлЭлСи Способы лечения системной красной волчанки, склеродермии и миозита
CN104603152A (zh) * 2012-06-13 2015-05-06 米迪缪尼有限公司 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
WO2017087634A1 (en) * 2015-11-17 2017-05-26 The Regents Of The University Of Colorado, A Body Corporate Novel multiplex assays to diagnose or evaluate diseases or disorders in mammals
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
CN118320101B (zh) * 2024-06-14 2024-09-17 天津嘉氏堂科技有限公司 iNOS抑制剂在制备治疗硬皮病胶原沉积药物中的应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3461808A (en) 1967-07-03 1969-08-19 Wood John Co Diaphragm hand pumps
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3923126A1 (de) 1989-07-13 1991-01-17 Stark Henric Lautsprecherbox
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US4997008A (en) 1990-04-26 1991-03-05 Moen Incorporated Faucet spout assembly
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2002320352A1 (en) * 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
CA2456753A1 (en) * 2001-08-17 2003-02-27 The Board Of Trustees Of The Leland Stanford Junior University Mammalian relaxin receptors
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
JP2008543335A (ja) * 2005-06-22 2008-12-04 ジェネンテック・インコーポレーテッド Ｉｆｎａｒ２を標的とするための方法と組成物
ES2432026T3 (es) * 2005-08-05 2013-11-29 Genentech, Inc. Métodos y composiciones para detectar trastornos autoinmunes
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus

Similar Documents

Publication Publication Date Title
Osei et al. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD
Branski et al. Acute vocal fold wound healing in a rabbit model
Sun et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia
Di Battista et al. One year in review 2021: systemic sclerosis
RU2008145510A (ru) Композиции и способы диагностики и лечения астмы или других аллергических или воспалительных заболеваний
JP2020508303A5 (enExample)
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
MX369466B (es) Inhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas.
JP2004529079A5 (enExample)
JP2012532859A5 (enExample)
Li et al. Inhibition of Dectin-1 in mice ameliorates cardiac remodeling by suppressing NF-κB/NLRP3 signaling after myocardial infarction
JP2014501492A5 (enExample)
Liang et al. Effects of interleukin 18 on injury and activation of human proximal tubular epithelial cells
Lu et al. Madecassoside ameliorates bleomycin‐induced pulmonary fibrosis in mice by downregulating collagen deposition
JP2011510647A5 (enExample)
JP2008528761A5 (enExample)
WO2021181368A1 (en) Methods of treating respiratory disease with deupirfenidone
ATE378051T1 (de) Nicotinrezeptor-agonisten zur behandlung von entzündlichen lungenerkrankungen
JP5749651B2 (ja) 多形核細胞の動員および／または遊走を減少させる化合物および方法
JP2018503685A5 (enExample)
Liu et al. MiRNA, a new treatment strategy for pulmonary fibrosis
RU2017122758A (ru) Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций
MX2011008074A (es) Macrolido anti-inflamatorio.
RU2010122644A (ru) Способы лечения склеродермии
Huang et al. Coptisine attenuates sepsis lung injury by suppressing LPS-induced lung epithelial cell inflammation and apoptosis